Uterine Fibroid Embolization (UFE) with Optisphere: A Prospective Study of a New, Spherical, Resorbable Embolic Agent
- 31 March 2020
- journal article
- research article
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (6) , 897-903
Abstract
Introduction Optisphere (Teleflex, Wayne, PA, USA, currently distributed by Medtronic, Minneapolis, MN, USA) is a new, resorbable, calibrated spherical embolic agent. We aimed to evaluate its clinical safety and effectiveness for fibroid embolization through a prospective case series. Method This prospective case series studied patients treated with fibroid embolization using Optisphere between July 2017 and June 2018. The primary outcomes were device-related adverse event assessments and MRI-determined percentage infarct of the dominant fibroid (DF %) and infarct of all fibroids (AF %) at 3 months post-embolization. Secondary outcomes included symptom improvement with the validated Uterine Fibroid Symptom Score and Quality of Life questionnaire (UFS-SS and UFS-QOL) at 3 months and 12 months post-embolization. Statistical analysis was through the Wilcoxon signed-rank test for nonparametric paired data. Results Twenty-three consecutive patients were treated with Optisphere (median age 44.0, uterine volume 484.0 ml, dominant fibroid volume 167.0 ml). The complete dominant fibroid infarction (DF %) rate was 91.3% (21/23 patients), and the complete all fibroid infarction rate (AF %) was 82.6% (19/23). No adverse device-related safety events were encountered. Significant improvement was demonstrated in 3-month UFS-SS (56 vs 19, p < 0.0001), UFS-QOL (40 vs 88, p = 0.0008), uterine volume (484 ml vs 246 ml, p < 0.0001) and dominant fibroid volume (167 vs 64 ml, p < 0.0001). Symptomatic improvement continued to 12 months (UFS-SS 56 vs 11, p = 0.0008, UFS-QOL 40 vs 98.7, p = 0.0008). Conclusion Optisphere is an effective embolic agent for fibroid embolization with good symptomatic response and percentage fibroid infarct.Keywords
Funding Information
- Teleflex
This publication has 24 references indexed in Scilit:
- Characterisation of physico-mechanical properties and degradation potential of calcium alginate beads for use in embolisationJournal of Materials Science: Materials in Medicine, 2010
- Impaired uterine perfusion in infertile women with repeated IVF-implantation failure as detected by uterine artery color Doppler studyFertility and Sterility, 2009
- An Overview of Embolic AgentsSeminars in Interventional Radiology, 2008
- Fetal Doppler: Umbilical Artery, Middle Cerebral Artery, and Venous SystemSeminars in Perinatology, 2008
- Leiomyoma Infarction after Uterine Artery Embolization: A Prospective Randomized Study Comparing Tris-acryl Gelatin Microspheres versus Polyvinyl Alcohol MicrospheresJournal of Vascular and Interventional Radiology, 2008
- Design of Cationic Microspheres Based on Aminated Gelatin for Controlled Release of Peptide and Protein DrugsDrug Delivery, 2008
- Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 years’ outcome from the randomized EMMY trialAmerican Journal of Obstetrics and Gynecology, 2007
- Fertility after bilateral uterine artery embolization in a sheep modelFertility and Sterility, 2007
- Biodegradable dextran-based microspheres for delivery of anticancer drug mitomycin CBiomaterials, 2005
- Uterine artery embolization – vascular anatomic considerations and procedure techniques2003